ATE141515T1 - Arzneistoffabgabe aus vp6-kapseln - Google Patents

Arzneistoffabgabe aus vp6-kapseln

Info

Publication number
ATE141515T1
ATE141515T1 AT92902950T AT92902950T ATE141515T1 AT E141515 T1 ATE141515 T1 AT E141515T1 AT 92902950 T AT92902950 T AT 92902950T AT 92902950 T AT92902950 T AT 92902950T AT E141515 T1 ATE141515 T1 AT E141515T1
Authority
AT
Austria
Prior art keywords
capsules
drug delivery
delivered
agents
encapsulated
Prior art date
Application number
AT92902950T
Other languages
English (en)
Inventor
Mark J Redmond
Manuel Dr Campos
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Application granted granted Critical
Publication of ATE141515T1 publication Critical patent/ATE141515T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92902950T 1991-02-04 1992-01-29 Arzneistoffabgabe aus vp6-kapseln ATE141515T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65005491A 1991-02-04 1991-02-04

Publications (1)

Publication Number Publication Date
ATE141515T1 true ATE141515T1 (de) 1996-09-15

Family

ID=24607266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92902950T ATE141515T1 (de) 1991-02-04 1992-01-29 Arzneistoffabgabe aus vp6-kapseln

Country Status (7)

Country Link
EP (1) EP0660723B1 (de)
JP (1) JPH06506667A (de)
AT (1) ATE141515T1 (de)
AU (1) AU660168B2 (de)
CA (1) CA2101735A1 (de)
DE (1) DE69213030D1 (de)
WO (1) WO1992013568A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
DE19750354A1 (de) * 1997-11-13 1999-05-27 November Ag Molekulare Medizin Verfahren zur Applikation von Wirkstoffen
DE19829005C2 (de) * 1998-06-29 2000-08-31 November Ag Molekulare Medizin Verfahren zum Transport molekularer Substanz in vorgegebene Bereiche eukaryontischer Zellen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3685651T2 (de) * 1985-12-26 1993-01-21 Univ Saskatchewan Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
CA1319101C (en) * 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US5186933A (en) * 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
PH26813A (en) * 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins

Also Published As

Publication number Publication date
AU1176892A (en) 1992-09-07
EP0660723B1 (de) 1996-08-21
JPH06506667A (ja) 1994-07-28
DE69213030D1 (de) 1996-09-26
CA2101735A1 (en) 1992-08-05
AU660168B2 (en) 1995-06-15
EP0660723A1 (de) 1995-07-05
WO1992013568A1 (en) 1992-08-20

Similar Documents

Publication Publication Date Title
MacEwen Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment
Washington et al. Physiological pharmaceutics: barriers to drug absorption
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ATE349438T1 (de) Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
ATE552859T1 (de) Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
AR002944A1 (es) Uso de una composicion de gel acuosa que contiene una o mas drogas que son eficaces para tratar hemorroides para la preparacion de un medicamento y dicha composicion de gel acuosa
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
AU7888398A (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
DE3868438D1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
GEP20032976B (en) Artificial Peptides Having Surface Activity and Use Thereof in The Preparation of Artificial Surfactant
ES2136673T3 (es) Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.
JPH04506659A (ja) 抗腫瘍溶液
RU94016167A (ru) Фармацевтическая композиция, способы доставки биологически активного вещества, способы лечения, способы стимулирования
ATE235513T1 (de) Opioid-konjugate mit endogenen trägerproteinen
Jin et al. 3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
DE69213030D1 (de) Arzneistoffabgabe aus VP6-Kapseln
GB2328872B (en) Method for preparing pharmaceutical formulations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties